Summary
Cencora, Inc. (COR) reported strong revenue growth in its fiscal third quarter of 2025, with an 8.7% increase year-over-year, reaching $80.7 billion. This growth was driven by solid performance across both its U.S. and International Healthcare Solutions segments. Notably, the U.S. segment saw a significant contribution from increased sales of GLP-1 class drugs for diabetes and weight loss, which grew 18.6% in the quarter. Profitability also showed improvement, with gross profit rising 20.6% year-over-year, largely due to higher sales volumes and the positive impact of a LIFO credit this year compared to an expense last year. The acquisition of Retina Consultants of America (RCA) in January 2025 has begun to contribute positively to the U.S. segment's results. While operating expenses increased, primarily due to integration costs from RCA, overall segment operating income grew by 20.6%. The company also continues to manage its debt effectively, with significant credit facility capacity, and reiterated its commitment to shareholder returns through dividends and share repurchases.
Financial Highlights
55 data points| Revenue | $80.66B |
| Cost of Revenue | $77.76B |
| Gross Profit | $2.91B |
| SG&A Expenses | $1.67B |
| Operating Income | $867.65M |
| Net Income | $687.40M |
| EPS (Basic) | $3.55 |
| EPS (Diluted) | $3.52 |
| Shares Outstanding (Basic) | 193.82M |
| Shares Outstanding (Diluted) | 195.23M |
Key Highlights
- 1Revenue increased by 8.7% to $80.7 billion for the third quarter, driven by strong performance in both U.S. and International segments.
- 2U.S. Healthcare Solutions segment revenue grew 8.5%, significantly boosted by a 18.6% increase in sales of GLP-1 class drugs.
- 3Gross profit saw a substantial increase of 20.6% year-over-year, aided by higher sales and a favorable LIFO credit.
- 4The acquisition of Retina Consultants of America (RCA) in January 2025 is contributing to the U.S. segment's revenue and profit growth.
- 5Operating income increased by 29.0% for the quarter, reflecting improved gross profit and operational efficiencies.
- 6The company has maintained robust liquidity, with substantial availability under its multi-currency revolving credit facility and receivables securitization facility.
- 7Cencora continues its share repurchase program, with $882.2 million remaining authorization as of June 30, 2025, and has increased its quarterly dividend.